Laboratorios Rubió is a company that is currently
undergoing a process of expansion and growth
(in thousands of €)
Laboratorios Rubió is a company in the process of expansion and growth. Ascending progression of turnover is an indicator of the good work done. Our strategic plan focuses on internationalization and R&D for the development of new products.
The turnover of 2022 totaled € 107,5 million, representing an annual increase of 38,3%. By markets, in Spain the increase has been 15,9% and 9,6% internationally.
2023 is expected to continue the growth in turnover reaching 110.2 M€, 2,5%.
The company’s staff is made up of 193 people—29,5% more than in 2022—with the greatest amount of growth happening in the sales and industrial operations departments.
Laboratorios Rubió is a company that places its trust in the people who make up its organisation, recognises their professional value and dedicates resources to ensure that a good working environment is maintained by fostering opportunities, personal development and a good work-life balance.
IWithin the company’s strategic plan to continue growing and promoting internationalization, in 2021 Laboratorios Rubió acquired the company Fisiopharma, specialized in nutraceuticals, betting on the food supplements market.
Laboratorios Rubió concentrates its investments on expanding production capacity and on R&D. In 2021, the expansion of the production facilities has begun, which in three years will allow us to practically double our capacity. We also continue to invest in various R&D projects for both the European and US markets.s.
Investments (in thousands of €)
Two major areas of Pharmaceutical and In-vitro Diagnosis
and nutrition for special conditions.
The activity of Rubió Laboratories is structured in two major areas of Pharmaceutical and In-vitro Diagnosis and nutrition for special conditions.
It has a large vademecum of medicines focused mainly on the therapeutic areas of Nephrology, Central Nervous System, Urology, Rheumatology, Cardiovascular Risk and Gynecology.
The company produces and sells medicines already consolidated in the market that have a solid reputation while introducing new products each year that arise both from their own development and from the agreement with third parties.
This area also encompasses healthcare products, an in-vitro diagnostic test focused on the determination of lipoprotein fractions (size / number) to determine cardiovascular risk, and development of complete formulas for the management of malnutrition in patients with chronic kidney disease.
Created in 2014, this subsidiary acts as a “patent box” in order to boost the Laboratorios Rubió’s R&D&i department. Within this sphere of activity, the company’s number one strategy is based on expanding the lifecycle of their own products, collaborating in new research programmes whose goals tie in with the company’s own therapeutic goals, and establishing strategic alliances with research foundations in related fields.
Biosfer Teslab, a spin-off of the Universidad Rovira i Virgili (URV) and the Institut d’Investigació Sanitària Pere Virgili (IISPV), is one of Laboratorios Rubió’s investee companies, which specialises in developing in vitro diagnostic tests to improve cardiovascular assessment in high-risk patients.
A national company specializing in nutraceuticals aimed at musculoskeletal health, which will grow in the coming years both in products from other therapeutic areas and in other countries.
